{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:11:03Z","timestamp":1771560663824,"version":"3.50.1"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Loan Repayment Program"],"award-info":[{"award-number":["Loan Repayment Program"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["Loan Repayment Program"],"award-info":[{"award-number":["Loan Repayment Program"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s13181-020-00777-5","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T17:04:31Z","timestamp":1588266271000},"page":"284-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["COVID-19: Therapeutics and Their Toxicities"],"prefix":"10.1007","volume":"16","author":[{"given":"Michael A.","family":"Chary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander F.","family":"Barbuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeh","family":"Izadmehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan D.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele M.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"key":"777_CR1","doi-asserted-by":"publisher","unstructured":"Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 Feb 24.\u00a0doi:\u00a0https:\/\/doi.org\/10.1016\/S2213-2600(20)30079-5.","DOI":"10.1016\/S2213-2600(20)30079-5"},{"key":"777_CR2","doi-asserted-by":"crossref","unstructured":"\u00d1amendys-Silva SA. Respiratory support for patients with COVID-19 infection. Lancet Respir Med. 2020\u00a0Apr;8(4):e18.","DOI":"10.1016\/S2213-2600(20)30110-7"},{"key":"777_CR3","doi-asserted-by":"crossref","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet.\u00a02020\u00a0Mar 28;395(10229):1033\u20131034.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"777_CR4","doi-asserted-by":"publisher","unstructured":"Zeng JH, Liu YX, Yuan J, Wang FX, Wu WB, Li JX, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights.\u00a0Infection.\u00a02020 Apr 10.\u00a0doi: https:\/\/doi.org\/10.1007\/s15010-020-01424-5.","DOI":"10.1007\/s15010-020-01424-5"},{"key":"777_CR5","doi-asserted-by":"publisher","unstructured":"Zheng YY,\u00a0Ma YT,\u00a0Zhang JY,\u00a0Xie X. COVID-19\u00a0and the\u00a0cardiovascular system.\u00a0Nat Rev Cardiol.\u00a02020\u00a0Mar 5. doi: https:\/\/doi.org\/10.1038\/s41569-020-0360-5.","DOI":"10.1038\/s41569-020-0360-5"},{"key":"777_CR6","doi-asserted-by":"publisher","unstructured":"Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.\u00a0Intensive Care Med.\u00a02020\u00a0Mar 3. doi:https:\/\/doi.org\/10.1007\/s00134-020-05991-x.","DOI":"10.1007\/s00134-020-05991-x"},{"key":"777_CR7","doi-asserted-by":"publisher","unstructured":"Xu B, Kraemer MUG, Open COVID-19 Data Curation Group.\u00a0 Open access epidemiological data from the COVID-19 outbreak.\u00a0\u00a0Lancet Infect Dis. 2020 Feb 19. doi:\u00a0https:\/\/doi.org\/10.1016\/S1473-3099(20)30119-5.","DOI":"10.1016\/S1473-3099(20)30119-5"},{"key":"777_CR8","unstructured":"Karimi N, Gambrell J. In Iran, False belief a poison fights virus kills hundreds. Associated Press, ABC News. 2020 Mar 27.\u00a0Accessed: 2020 Apr 2."},{"key":"777_CR9","unstructured":"Coronavirus cannot be cured by drinking bleach or snorting cocaine, despite social media rumors. Scottsdale Recovery Center [Internet]. 2020 Mar 11.https:\/\/scottsdalerecovery.com\/coronavirus-cannot-be-cured-by-drinking-bleach-or-snorting-cocaine-despite-social-media-rumors\/. Accessed: 17 Mar 2020."},{"key":"777_CR10","unstructured":"Gandel S. Facebook coronavirus posts spread misinformation on deadly outbreak. CBS News. 2020 Jan 29.https:\/\/www.cbsnews.com\/news\/facebook-coronavirus-posts-spread-misinformation-on-deadly-outbreak\/. Accessed: 17 Mar 2020."},{"key":"777_CR11","unstructured":"Misinformation related to the 2019\u201320 coronavirus outbreak. Wikipedia. 2020; https:\/\/en.wikipedia.org\/wiki\/Misinformation_related_to_the_2019\u201320_coronavirus_pandemic. Accessed: 2 Apr 2020."},{"key":"777_CR12","doi-asserted-by":"crossref","unstructured":"Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature.\u00a02020 Mar;579(7798):270\u2013273.\u00a0","DOI":"10.1038\/s41586-020-2012-7"},{"key":"777_CR13","doi-asserted-by":"crossref","unstructured":"Callaway E. Coronavirus vaccines: five key questions as trials begin. Nature.\u00a02020 Mar;579(7800):481.","DOI":"10.1038\/d41586-020-00798-8"},{"key":"777_CR14","unstructured":"Bright R. Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 Coronavirus Disease 2020; https:\/\/www.fda.gov\/media\/136534\/download. Accessed: 5 Apr 2020."},{"key":"777_CR15","unstructured":"Medicines Agency E. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes [Internet]. https:\/\/www.ema.europa.eu\/en\/news\/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes. Accessed: 5 Apr 2020."},{"key":"777_CR16","unstructured":"The\u00a0American Academy of Clinical Toxicology, The\u00a0American College of Medical Toxicology\u00a0and the\u00a0American Association of Poison Control Centers. Joint Statement Press Release: Caution About Toxicity From Hydroxychloroquine and Chloroquine. https:\/\/mailchi.mp\/clintox\/aact-acmt-aapcc-joint-statement.\u00a020 Mar 2020.\u00a0"},{"key":"777_CR17","doi-asserted-by":"crossref","unstructured":"Hempelmann E. Hemozoin biocrystallization in plasmodium falciparum and the antimalarial activity of crystallization inhibitors. Parasitol Res. 2007;100:671\u20136.","DOI":"10.1007\/s00436-006-0313-x"},{"key":"777_CR18","doi-asserted-by":"crossref","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.","DOI":"10.1186\/1743-422X-2-69"},{"key":"777_CR19","doi-asserted-by":"crossref","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol.\u00a02020\u00a0Mar;16(3):155\u2013166.","DOI":"10.1038\/s41584-020-0372-x"},{"key":"777_CR20","unstructured":"Multicenter collaboration group of department of science and technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert Consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi.\u00a02020 Feb 20;43(0):E019."},{"key":"777_CR21","doi-asserted-by":"crossref","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res.\u00a02020 Mar;30(3):269\u2013271.","DOI":"10.1038\/s41422-020-0282-0"},{"key":"777_CR22","doi-asserted-by":"crossref","unstructured":"Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.\u00a0Biosci Trends.\u00a02020 Mar 16;14(1):72\u201373.","DOI":"10.5582\/bst.2020.01047"},{"key":"777_CR23","doi-asserted-by":"crossref","unstructured":"Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. N Engl J Med.\u00a01988 Jan 7;318(1):1\u20136.","DOI":"10.1056\/NEJM198801073180101"},{"key":"777_CR24","unstructured":"Waldrop T, Alsup D, McLaughlin EC. Fearing coronavirus, Arizona man dies after taking a form of chloroquine used in aquariums. CNN [Internet]. 2020 Mar 23. https:\/\/www.cnn.com\/2020\/03\/23\/health\/arizona-coronavirus-chloroquine-death\/index.html. Accessed: 24 Mar 2020."},{"key":"777_CR25","unstructured":"Busari S, Bukola A. Nigeria records chloroquine poisoning after Trump endorses it for coronavirus treatment. CNN [Internet]. 2020 Mar 23.https:\/\/www.cnn.com\/2020\/03\/23\/africa\/chloroquine-trump-nigeria-intl\/index.html. Accessed: 24 Mar 2020."},{"key":"777_CR26","doi-asserted-by":"crossref","unstructured":"Jaeger A, Sauder P, Kopferschmitt J, Flesch F. Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol Adverse Drug Exp. 1987;2:242\u201373.","DOI":"10.1007\/BF03259868"},{"key":"777_CR27","doi-asserted-by":"crossref","unstructured":"Guly U, Driscoll P. The management of quinine-induced blindness. Arch Emerg Med. 1992;9:317\u201322.","DOI":"10.1136\/emj.9.3.317"},{"key":"777_CR28","doi-asserted-by":"crossref","unstructured":"Smith ER, Klein-Schwartz W, Love JN. Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med.\u00a02005 May;28(4):437\u201343.","DOI":"10.1016\/j.jemermed.2004.12.011"},{"key":"777_CR29","doi-asserted-by":"crossref","unstructured":"Kim KA, Park JY, Lee JS, Lim S. Cytochrome P450 2C8 and CYP3A4\/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res.\u00a02003 Aug;26(8):631\u20137.","DOI":"10.1007\/BF02976712"},{"key":"777_CR30","doi-asserted-by":"crossref","unstructured":"Somer M, Kallio J, Pesonen U, Pyykk\u00f6 K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol.\u00a02000 Jun;49(6):549\u201354.","DOI":"10.1046\/j.1365-2125.2000.00197.x"},{"key":"777_CR31","doi-asserted-by":"crossref","unstructured":"Ling Ngan Wong A, Tsz Fung Cheung I, Graham CA. Hydroxychloroquine overdose: case report and recommendations for management. Eur J Emerg Med. 2008;15:16\u20138.","DOI":"10.1097\/MEJ.0b013e3280adcb56"},{"key":"777_CR32","doi-asserted-by":"crossref","unstructured":"Dalley RA, Hainsworth D. Fatal plaquenil poisoning. J Forensic Sci Soc.\u00a01965 Apr;5(2):99\u2013101.","DOI":"10.1016\/S0015-7368(65)70251-X"},{"key":"777_CR33","doi-asserted-by":"crossref","unstructured":"Jordan P, Brookes JG, Nikolic G, Le Couteur DG. Hydroxychloroquine overdose: toxicokinetics and management. J Toxicol Clin Toxicol.\u00a01999;37(7):861\u20134.","DOI":"10.1081\/CLT-100102466"},{"key":"777_CR34","doi-asserted-by":"crossref","unstructured":"Yanturali S, Aksay E, Demir OF, Atilla R. Massive hydroxychloroquine overdose. Acta Anaesthesiol Scand.\u00a02004 Mar;48(3):379\u201381.","DOI":"10.1111\/j.0001-5172.2004.0302.x"},{"key":"777_CR35","doi-asserted-by":"crossref","unstructured":"Gunja N, Roberts D, McCoubrie D, Lamberth P, Jan A, Simes DC, et al. Survival after massive hydroxychloroquine overdose. Anaesth Intensive Care.\u00a02009 Jan;37(1):130\u20133.","DOI":"10.1177\/0310057X0903700112"},{"key":"777_CR36","doi-asserted-by":"crossref","unstructured":"de Olano J, Howland MA, Su MK, Hoffman RS, Biary R. Toxicokinetics of hydroxychloroquine following a massive overdose. Am J Emerg Med.\u00a02019 Dec;37(12):2264.e5\u20132264.e8.\u00a0","DOI":"10.1016\/j.ajem.2019.158387"},{"key":"777_CR37","doi-asserted-by":"publisher","unstructured":"Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv.\u00a02020 Apr 10. https:\/\/doi.org\/10.1101\/2020.03.22.20040758.\u00a0","DOI":"10.1101\/2020.03.22.20040758"},{"key":"777_CR38","doi-asserted-by":"crossref","unstructured":"Crouzette J, Vicaut E, Palombo S, Girre C, Fournier PE. Experimental assessment of the protective activity of diazepam on the acute toxicity of chloroquine.\u00a0 J Toxicol Clin Toxicol.\u00a01983 May;20(3):271\u20139.","DOI":"10.3109\/15563658308990070"},{"key":"777_CR39","doi-asserted-by":"crossref","unstructured":"Clemessy JL, Borron SW, Baud FJ, Favier C, Hantson PE, Vicaut E. Hypokalaemia related to acute chloroquine ingestion. Lancet.\u00a01995 Sep 30;346(8979):877\u201380.","DOI":"10.1016\/S0140-6736(95)92711-5"},{"key":"777_CR40","doi-asserted-by":"crossref","unstructured":"Wong O, Chan Y, Lam S, Fung H, Ho J. Clinical experience in the use of intravenous lipid emulsion in hydroychloroquine and chloroquine overdose with refractory shock. Hong Kong J Emerg Med. 2011;18:243\u20138.","DOI":"10.1177\/102490791101800410"},{"key":"777_CR41","doi-asserted-by":"crossref","unstructured":"Murphy LR, Maskell KF, Kmiecik KJ, Shaffer BM. Intravenous lipid emulsion use for severe Hydroxychloroquine toxicity. Am J Ther.\u00a02018 Mar\/Apr;25(2):e273\u2013e275.\u00a0","DOI":"10.1097\/MJT.0000000000000451"},{"key":"777_CR42","unstructured":"Ten Broeke R, Mestrom E, Woo L, Kreeftenberg H. Early treatment with intravenous lipid emulsion in a potentially lethal hydroxychloroquine intoxication. Neth J Med.\u00a02016 Jun;74(5):210\u20134."},{"key":"777_CR43","doi-asserted-by":"crossref","unstructured":"Mongenot F, Gonthier YT, Derderian F, Durand M, Blin D. Treatment of hydroxychloroquine poisoning with extracorporeal circulation. Ann Fr Anesth Reanim.\u00a02007 Feb;26(2):164\u20137.","DOI":"10.1016\/j.annfar.2006.09.005"},{"key":"777_CR44","doi-asserted-by":"crossref","unstructured":"Frederick W, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res.\u00a02010 Jun;62(6):775\u201384.","DOI":"10.1002\/acr.20133"},{"key":"777_CR45","doi-asserted-by":"crossref","unstructured":"Muthukrishnan P, Roukoz H, Grafton G, Jessurun J, Colvin-Adams M. Hydroxychloroquine-induced cardiomyopathy: a case report. Circ Heart Fail.\u00a02011 Mar;4(2):e7\u20138.","DOI":"10.1161\/CIRCHEARTFAILURE.110.959916"},{"key":"777_CR46","doi-asserted-by":"crossref","unstructured":"Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care.\u00a02013 Mar;2(1):77\u201383.","DOI":"10.1177\/2048872612471215"},{"key":"777_CR47","unstructured":"Ornstein C. Lupus patients can\u2019t get crucial medication after President Trump pushes unproven coronavirus treatment. ProPublica [Internet]. 2020 Mar 22.\u00a0https:\/\/www.propublica.org\/article\/lupus-patients-cant-get-crucial-medication-after-president-trump-pushes-unproven-coronavirus-treatment. Accessed 24 Mar 2020."},{"key":"777_CR48","unstructured":"Gabler E. States Say Some Doctors Stockpile Trial Coronavirus Drugs, for Themselves. The New York Times [Internet]. 2020 Mar 23.https:\/\/www.nytimes.com\/2020\/03\/24\/business\/coronavirus-doctors-hoard-drugs.html. Accessed 24 Mar 2020."},{"key":"777_CR49","doi-asserted-by":"crossref","unstructured":"Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep.\u00a02014 Nov 13;4:7027.","DOI":"10.1038\/srep07027"},{"key":"777_CR50","doi-asserted-by":"crossref","unstructured":"Monteil V, Kwon H, Prado P, Hagelkr\u00fcys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2.\u00a0Endocrine Reviews.\u00a02020.","DOI":"10.1016\/j.cell.2020.04.004"},{"key":"777_CR51","doi-asserted-by":"crossref","unstructured":"Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.\u00a0Intensive\u00a0Care\u00a0Med.\u00a02020 Apr;46(4):586\u2013590.\u00a0","DOI":"10.1007\/s00134-020-05985-9"},{"key":"777_CR52","doi-asserted-by":"crossref","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature.\u00a02005 Jul 7;436(7047):112\u20136.","DOI":"10.1038\/nature03712"},{"key":"777_CR53","unstructured":"Pilot clinical trial in China to test UBC researcher\u2019s findings as a targeted therapy for COVID-19.\u00a0\u00a0The University of British Columbia [Internet].\u00a0\u00a02020 Feb 25.\u00a0https:\/\/www.med.ubc.ca\/news\/pilot-clinical-trial-in-china-to-test-ubc-researchers-findings-as-a-targeted-therapy-for-covid-19\/. Accessed 22 Mar 2020."},{"key":"777_CR54","unstructured":"Schuster M, Peball B. rhACE2: cloning to clinic detection and quantification of circulating epithelial tumor cells. Gordon Res Conf Mol Basis Action, Dysfunct New Ther Approaches. 2010."},{"key":"777_CR55","doi-asserted-by":"crossref","unstructured":"Murphy PM. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol.\u00a02001 Feb;2(2):116\u201322.","DOI":"10.1038\/84214"},{"key":"777_CR56","doi-asserted-by":"crossref","unstructured":"Marques RE, Guabiraba R, Del Sarto JL, Rocha RF, Queiroz AL, Cisalpino D, et al. Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development. Immunology.\u00a02015 Aug;145(4):583\u201396.","DOI":"10.1111\/imm.12476"},{"key":"777_CR57","doi-asserted-by":"crossref","unstructured":"Vangelista L, Vento S. The expanding therapeutic perspective of CCR5 blockade. Front Immunol.\u00a02018 Jan 12;8:1981.\u00a0","DOI":"10.3389\/fimmu.2017.01981"},{"key":"777_CR58","doi-asserted-by":"crossref","unstructured":"Jiao X, Nawab O, Patel T, Kossenkov A V., Halama N, Jaeger D, et al. Recent advances targeting CCR5 for cancer and its role in immuno-oncology. Cancer Res. 2019 Oct 1; 79(19): 4801\u20134807.","DOI":"10.1158\/0008-5472.CAN-19-1167"},{"key":"777_CR59","unstructured":"Search of: Leronlimab (ClinicalTrials.gov). U.S. National Library of Medicine\u00a0[Internet]. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=leronlimab&cntry=&state=&city=&dist=. Accessed 7 Apr 2020."},{"key":"777_CR60","doi-asserted-by":"crossref","unstructured":"Descotes J. Immunotoxicity of monoclonal antibodies. MAbs.\u00a02009 Mar-Apr;1(2):104\u201311.\u00a0","DOI":"10.4161\/mabs.1.2.7909"},{"key":"777_CR61","doi-asserted-by":"crossref","unstructured":"Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs.\u00a02010 May-Jun;2(3):256\u201365.\u00a0","DOI":"10.4161\/mabs.2.3.11641"},{"key":"777_CR62","doi-asserted-by":"crossref","unstructured":"Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. The Ambiguous Base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2032-triphosphate towards influenza a virus polymerase. PLoS One.\u00a02013 Jul 10;8(7):e68347.\u00a0","DOI":"10.1371\/journal.pone.0068347"},{"key":"777_CR63","doi-asserted-by":"crossref","unstructured":"Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002 Mar 15;34(6):838\u201346.\u00a0","DOI":"10.1086\/339041"},{"key":"777_CR64","doi-asserted-by":"crossref","unstructured":"Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther.\u00a02000 Aug;22(8):911\u201336; discussion 898.","DOI":"10.1016\/S0149-2918(00)80064-8"},{"key":"777_CR65","doi-asserted-by":"crossref","unstructured":"Barry M, Howe JL, Back DJ, Swart AM, Breckenridge AM, Weller IV, et al. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. Br J Clin Pharmacol. 1994 Jan; 37(1): 7\u201312.","DOI":"10.1111\/j.1365-2125.1994.tb04231.x"},{"key":"777_CR66","doi-asserted-by":"crossref","unstructured":"Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem.\u00a02001 Nov 2;276(44):40847\u201357.\u00a0","DOI":"10.1074\/jbc.M106743200"},{"key":"777_CR67","doi-asserted-by":"crossref","unstructured":"Hall AM. Update on tenofovir toxicity in the kidney. Pediatr Nephrol.\u00a02013 Jul;28(7):1011\u201323.\u00a0","DOI":"10.1007\/s00467-012-2269-7"},{"key":"777_CR68","doi-asserted-by":"publisher","unstructured":"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science.\u00a02020 Mar 20. doi:\u00a0https:\/\/doi.org\/10.1126\/science.abb3405.","DOI":"10.1126\/science.abb3405"},{"key":"777_CR69","doi-asserted-by":"crossref","unstructured":"Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun.\u00a02004 Jun 4;318(3):719\u201325.","DOI":"10.1016\/j.bbrc.2004.04.083"},{"key":"777_CR70","doi-asserted-by":"crossref","unstructured":"Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar; 59(3): 252\u2013256.","DOI":"10.1136\/thorax.2003.012658"},{"key":"777_CR71","doi-asserted-by":"crossref","unstructured":"Hull MW, Montaner JSG. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med.\u00a02011 Aug;43(5):375\u201388.\u00a0","DOI":"10.3109\/07853890.2011.572905"},{"key":"777_CR72","doi-asserted-by":"crossref","unstructured":"Park SY, Lee JS, Son JS, Ko JH, Peck KR, Jung Y, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infect.\u00a02019\u00a0Jan;101(1):42\u201346.\u00a0","DOI":"10.1016\/j.jhin.2018.09.005"},{"key":"777_CR73","doi-asserted-by":"publisher","unstructured":"Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic\u00a0Features\u00a0and\u00a0Clinical\u00a0Course\u00a0of\u00a0Patients\u00a0Infected\u00a0With\u00a0SARS-CoV-2\u00a0in\u00a0Singapore.\u00a0JAMA.\u00a02020 Mar 3. doi:\u00a0https:\/\/doi.org\/10.1001\/jama.2020.3204.","DOI":"10.1001\/jama.2020.3204"},{"key":"777_CR74","doi-asserted-by":"publisher","unstructured":"Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis.\u00a02020\u00a0Mar 12. doi:\u00a0https:\/\/doi.org\/10.1016\/j.ijid.2020.03.013.","DOI":"10.1016\/j.ijid.2020.03.013"},{"key":"777_CR75","doi-asserted-by":"publisher","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19.\u00a0N Engl J Med.\u00a02020\u00a0Mar 18. doi: https:\/\/doi.org\/10.1056\/NEJMoa2001282.\u00a0","DOI":"10.1056\/NEJMoa2001282"},{"key":"777_CR76","doi-asserted-by":"crossref","unstructured":"Roberts DM, Ray JE, Buckley NA. Mild clinical toxicity and dose-dependent pharmacokinetics following acute lopinavir\/ritonavir poisoning in a HIV-positive patient. AIDS.\u00a02008 Mar 30;22(6):792\u20133.","DOI":"10.1097\/QAD.0b013e3282f4a0dd"},{"key":"777_CR77","doi-asserted-by":"crossref","unstructured":"Rock BM,\u00a0Hengel SM,\u00a0Rock DA,\u00a0Wienkers LC,\u00a0Kunze KL. Characterization of ritonavir-mediated inactivation of\u00a0cytochrome\u00a0P450 3A4. Mol Pharmacol.\u00a02014 Dec;86(6):665\u201374.\u00a0","DOI":"10.1124\/mol.114.094862"},{"key":"777_CR78","unstructured":"Grayson ML, Cosgrove S, Crowe SM, Hope W, McCarthy JS, Mills J et al.\u00a0Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press. 2017. p. 1\u20134841"},{"key":"777_CR79","doi-asserted-by":"crossref","unstructured":"Garzel B, Yang H, Zhang L, Huang SM, Polli JE, Wang H. The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity. Drug Metab Dispos.\u00a02014 Mar;42(3):318\u201322.\u00a0","DOI":"10.1124\/dmd.113.054189"},{"key":"777_CR80","doi-asserted-by":"crossref","unstructured":"L\u00f3pez Aspiroz E, Cabrera Figueroa S Enrique, Iglesias G\u00f3mez A, Valverde Merino MP, Dom\u00ednguez-Gil Hurl\u00e9 A. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman. Clin Drug Investig. 31 Dec 2014, 35(1):61\u201366","DOI":"10.1007\/s40261-014-0245-7"},{"key":"777_CR81","doi-asserted-by":"crossref","unstructured":"Aspiroz EL, Figueroa SEC, Cruz R, Porras Hurtado GL, Mart\u00edn AF, Hurl\u00e9 ADG, et al. Toxicogenetics of lopinavir\/ritonavir in HIV-infected European patients. Per Med.\u00a02014 May;11(3):263\u2013272.","DOI":"10.2217\/pme.14.7"},{"key":"777_CR82","doi-asserted-by":"crossref","unstructured":"Florence E,\u00a0Schrooten W,\u00a0Verdonck K,\u00a0Dreezen C,\u00a0Colebunders R. Rheumatological\u00a0complications\u00a0associated\u00a0with the use of\u00a0indinavir\u00a0and\u00a0other\u00a0protease inhibitors.\u00a0Ann Rheum Dis.\u00a02002 Jan;61(1):82\u20134.\u00a0","DOI":"10.1136\/ard.61.1.82"},{"key":"777_CR83","doi-asserted-by":"crossref","unstructured":"Cresswell F V, Tomlins J, Churchill DR, Walker-Bone K, Richardson D. Achilles tendinopathy following Kaletra (lopinavir\/ritonavir) use. Int J STD AIDS.\u00a02014 Oct;25(11):833\u20135.\u00a0","DOI":"10.1177\/0956462414523403"},{"key":"777_CR84","doi-asserted-by":"crossref","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science.\u00a02020 Mar 13;367(6483):1260\u20131263.\u00a0","DOI":"10.1126\/science.abb2507"},{"key":"777_CR85","doi-asserted-by":"crossref","unstructured":"Walls A, Tortorici M, Bosch B, Frenz B,\u00a0Rottier PJM,\u00a0DiMaio F,\u00a0et al.\u00a0Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature.\u00a02016 Mar 3;531(7592):114\u2013117.","DOI":"10.1038\/nature16988"},{"key":"777_CR86","doi-asserted-by":"crossref","unstructured":"Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA Vaccines. Annu Rev Immunol. 1997;15:617\u201348.","DOI":"10.1146\/annurev.immunol.15.1.617"},{"key":"777_CR87","doi-asserted-by":"crossref","unstructured":"Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines.\u00a02012 Feb;11(2):189\u2013209.","DOI":"10.1586\/erv.11.188"},{"key":"777_CR88","doi-asserted-by":"crossref","unstructured":"Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis Lancet Publishing Group; 2019;19:1013\u201322.","DOI":"10.1016\/S1473-3099(19)30266-X"},{"key":"777_CR89","unstructured":"Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800. Inovio Pharmaceuticals, Inc\u00a0[Internet].\u00a02020 Mar 3.\u00a0http:\/\/ir.inovio.com\/news-and-media\/news\/press-release-details\/2020\/Inovio-Accelerates-Timeline-for-COVID-19-DNA-Vaccine-INO-4800\/default.aspx. Accessed 22 Mar 2020."},{"key":"777_CR90","doi-asserted-by":"crossref","unstructured":"Schommer NN, Nguyen J, Yung BS, Schultheis K, Muthumani K, Weiner DB, et al. Active immunoprophylaxis and vaccine augmentations mediated by a novel plasmid DNA formulation. Hum Gene Ther.\u00a02019 Apr;30(4):523\u2013533.","DOI":"10.1089\/hum.2018.241"},{"key":"777_CR91","doi-asserted-by":"crossref","unstructured":"Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, Sardesai NY, Bagarazzi ML. Tolerability of intramuscular and intradermal delivery by CELLECTRA\u00ae adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother.\u00a02013 Oct;9(10):2246\u201352.","DOI":"10.4161\/hv.24702"},{"key":"777_CR92","doi-asserted-by":"crossref","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov.\u00a02018 Apr;17(4):261\u2013279.","DOI":"10.1038\/nrd.2017.243"},{"key":"777_CR93","doi-asserted-by":"publisher","unstructured":"Hodgson J. The pandemic pipeline. Nat Biotechnol. 2020 Mar 20. doi:\u00a0https:\/\/doi.org\/10.1038\/d41587-020-00005-z.","DOI":"10.1038\/d41587-020-00005-z"},{"key":"777_CR94","doi-asserted-by":"crossref","unstructured":"Parnham MJ, Haber VE, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: Mechanisms of action and their relevance for clinical applications.\u00a0Pharmacol Ther.\u00a02014 Aug;143(2):225\u201345.","DOI":"10.1016\/j.pharmthera.2014.03.003"},{"key":"777_CR95","doi-asserted-by":"publisher","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents.\u00a02020 Mar 20.\u00a0doi: https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949.\u00a0\u00a0","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"777_CR96","doi-asserted-by":"crossref","unstructured":"Goldstein EJC, Owens Jr RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis.\u00a02006 Dec 15;43(12):1603\u201311.\u00a0","DOI":"10.1086\/508873"},{"key":"777_CR97","doi-asserted-by":"crossref","unstructured":"Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med.\u00a02012 May 17;366(20):1881\u201390.\u00a0","DOI":"10.1056\/NEJMoa1003833"},{"key":"777_CR98","doi-asserted-by":"crossref","unstructured":"Svanstr\u00f6m H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013 May 2;368(18):1704\u201312.","DOI":"10.1056\/NEJMoa1300799"},{"key":"777_CR99","doi-asserted-by":"crossref","unstructured":"Baker WL, Couch KA. Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis.\u00a0Am J Health Syst Pharm.\u00a02007 Apr 15;64(8):830\u20136.","DOI":"10.2146\/ajhp060539"},{"key":"777_CR100","unstructured":"Tucker ME. ESC Says Continue Hypertension Meds Despite COVID-19 Concern. Medscape [Internet]. 2020 Mar 16.\u00a0https:\/\/www.medscape.com\/viewarticle\/926838. Accessed 17 Mar 2020."},{"key":"777_CR101","doi-asserted-by":"crossref","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?\u00a0Lancet Respir Med.\u00a02020\u00a0Apr;8(4):e21.","DOI":"10.1016\/S2213-2600(20)30116-8"},{"key":"777_CR102","doi-asserted-by":"publisher","unstructured":"Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.\u00a0Drug Dev Res.\u00a02020 Mar 4. doi:\u00a0https:\/\/doi.org\/10.1002\/ddr.21656.","DOI":"10.1002\/ddr.21656"},{"key":"777_CR103","doi-asserted-by":"crossref","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med.\u00a02005 Aug;11(8):875\u20139.","DOI":"10.1038\/nm1267"},{"key":"777_CR104","doi-asserted-by":"crossref","unstructured":"Vaur L, Bobrie G, Dutrey-Dupagne C, Dubroca I, Vaisse B, D\u2019Yvoire MB, et al. Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients. Am J Hypertens.\u00a01998 Feb;11(2):165\u201373.","DOI":"10.1016\/S0895-7061(97)00420-2"},{"key":"777_CR105","unstructured":"World Health Organization (WHO) on Twitter: \u201cQ: Could #ibuprofen worsen disease for people with #COVID19? A: Based on currently available information, WHO does not recommend against the use of of ibuprofen. https:\/\/t.co\/n39DFt2amF\u201d \/ Twitter [Internet]. https:\/\/twitter.com\/WHO\/status\/1240409217997189128. Accessed: 2020 Mar 22."},{"key":"777_CR106","unstructured":"FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. FDA [Internet]. 2020 Mar 19.https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19. Accessed 24 Mar 2020."},{"key":"777_CR107","doi-asserted-by":"publisher","unstructured":"Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A.\u00a02020 Apr 6. doi: https:\/\/doi.org\/10.1073\/pnas.2004168117.","DOI":"10.1073\/pnas.2004168117"},{"key":"777_CR108","doi-asserted-by":"publisher","unstructured":"Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA.\u00a02020 Mar 27. doi:\u00a0https:\/\/doi.org\/10.1001\/jama.2020.4783.","DOI":"10.1001\/jama.2020.4783"},{"key":"777_CR109","doi-asserted-by":"crossref","unstructured":"Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012 May; 52(Suppl 1): 65S\u201379S.","DOI":"10.1111\/j.1537-2995.2012.03663.x"},{"key":"777_CR110","doi-asserted-by":"crossref","unstructured":"Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80\u201390.","DOI":"10.1093\/infdis\/jiu396"},{"key":"777_CR111","doi-asserted-by":"publisher","unstructured":"Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020 Mar 31. doi: https:\/\/doi.org\/10.1016\/j.chest.2020.03.039.","DOI":"10.1016\/j.chest.2020.03.039"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-020-00777-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-020-00777-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-020-00777-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T17:59:05Z","timestamp":1666461545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-020-00777-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s13181-020-00777-5","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Burns is the Pediatric Toxicology Section Editor for <i>UpToDate<\/i>. No other authors report conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}